ArticleFrontiers in cardiovascular medicine2026
Clinical characteristics of gut microbiota translocation after acute myocardial infarction and its impact on prognosis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To systematically analyze the clinical characteristics of gut microbiota translocation in patients after acute myocardial infarction (AMI), explore the relationships among intestinal barrier dysfunction, gut microbiota changes, inflammatory response, and cardiac function impairment, and further evaluate its association with short-term prognosis, so as to provide new clinical evidence for risk stratification and comprehensive intervention in AMI patients. Methods: This study adopted a single-center retrospective cohort design. A total of 148 patients with AMI who were hospitalized in the Department of Cardiology of our hospital and received standardized treatment from April 2023 to June 2025 were selected as the study subjects (AMI group), and 110 healthy volunteers who underwent physical examination during the same period were included as the control group. Venous blood and fecal samples had been collected within 24 h after admission or on the day of physical examination as part of the routine clinical laboratory or health examination workflow, and the corresponding laboratory results were retrospectively extracted for this study. Serum D-lactic acid (D-LA), diamine oxidase (DAO), and lipopolysaccharide (LPS) levels were detected by enzyme-linked immunosorbent assay to evaluate intestinal barrier function and microbiota translocation; the quantities of five representative gut microbiota, including Bifidobacterium, Lactobacillus, Bacteroides, Enterobacter, and Enterococcus, were detected by gut microbiota culture. According to serum LPS levels and intestinal barrier indicators, the presence of gut microbiota translocation was comprehensively determined, and patients were divided into a translocation group ( Results: Compared with the control group, serum D-LA, DAO, and LPS levels were significantly increased in the AMI group ( Conclusion: AMI patients exhibit marked intestinal barrier dysfunction and gut microbiota translocation during the acute phase, characterized by elevated levels of D-LA, DAO, and LPS, with concomitant decreases in putatively beneficial or commensal bacteria, including Bifidobacterium, Lactobacillus, and Bacteroides, and increases in opportunistic/pathobiont bacteria such as Enterobacter and Enterococcus. The degree of gut microbiota translocation is closely associated with enhanced inflammatory response, worsening cardiac function, and the occurrence of short-term adverse cardiovascular events, suggesting that the " gut-heart axis " may play an important role in disease progression and prognostic evolution after AMI. Intestinal barrier function and microbiota translocation-related indicators may serve as potential auxiliary biomarkers for prognostic risk assessment in AMI patients and provide new research directions for future gut microbiota intervention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.